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Abstract 
Photodynamic therapy (PDT) is an emerging theranostic modality for various cancers and 
diseases. The focus of this study was the development of tumor-targeting albumin nanopar-
ticles containing photosensitizers for efficient PDT. To produce tumor-targeting albumin 
nanoparticles, the hydrophobic photosensitizer, chlorin e6 (Ce6), was chemically conjugated 
to human serum albumin (HSA). The conjugates formed self-assembled nanoparticle struc-
tures  with an  average  diameter of  88 nm  under aqueous  conditions. As  expected,  the 
Ce6-conjugated HSA nanoparticles (Ce6-HSA-NPs) were nontoxic in their native state, but 
upon illumination with the appropriate wavelength of light, they produced singlet oxygen and 
damaged target tumor cells in a cell culture system. Importantly, when the nanoparticles were 
injected through the tail vein into tumor-bearing HT-29 mice, Ce6-HSA-NPs compared with 
free Ce6 revealed enhanced tumor-specific biodistribution and successful therapeutic results 
following laser irradiation. These results suggest that highly tumor-specific albumin nanopar-
ticles have the potential to serve not only as efficient therapeutic agents, but also as photo-
dynamic imaging (PDI) reagents in cancer treatment. 
Key words: Photodynamic therapy, Human Serum Albumin Nanoparticles 
Introduction 
Photodynamic  therapy  (PDT)  is  an  effective 
medical tool for treating various cancers by inducing 
cell apoptosis or necrosis [1-3]. Photodynamic therapy 
is a theranostic treatment that uses chemical photo-
sensitization  and  light  irradiation  at  specific  wave-
lengths to eradicate  target tumor tissues. In the ab-
sence of light, photosensitizers are nontoxic to cells, 
but when illuminated with specific activating wave-
lengths,  the  photosensitizers  generate  cytotoxic  sin-
glet oxygen that destroys cells through the aforemen-
tioned mechanisms [4, 5]. In addition, photosensitiz-
ers are able to provide intense fluorescence signals in Theranostics 2011, 1 
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tumor tissues that allow their photodynamic imaging 
(PDI). Therefore, the selective accumulation of pho-
tosensitizers  in  target  tumor  tissues  can  be  concur-
rently employed for both PDI and PDT. However, the 
use  of  photosensitizers  has  been  limited  in  clinical 
applications because of their poor water solubility and 
low tumor-targeting efficacy [6].  
To overcome these limitations of photosensitiz-
ers for PDI and PDT, various nano-sized drug carriers 
such as polymeric micelles, emulsions, and nanopar-
ticles  have  been  developed  to  enhance  their  water 
solubility  and  tumor-targeting  efficacy  [7-10]. 
Nano-sized drug carriers are known to accumulate at 
the tumor site by the so-called enhanced permeation 
and retention (EPR) effect, resulting in efficient pas-
sive accumulation in solid tumor tissues [11]. There-
fore, various photosensitizer-encapsulated nano-sized 
carriers could enhance tumor-targeting specificity and 
therapeutic efficacy in cancer treatment in comparison 
with  free  photosensitizers  [4,  8,  9].  Recently,  these 
photosensitizer-encapsulated  drug  carriers  have 
shown great promise for theranostic multifunctional 
nanoparticles for both the diagnosis and therapeutic 
treatment of cancers [8]. 
Human serum albumin (HSA) has attracted re-
cent interest as a theranostic drug carrier due to its 
abundance,  biocompatibility,  and  versatile  roles  in 
imaging and drug delivery [12, 13]. Moreover, accu-
mulation of albumin at the target tumor tissue pro-
vides a rationale for the development of HSA-based 
drug  delivery  systems  for  cancer  treatment.  In  pre-
vious  studies,  HSA-based  nanoparticles  were  made 
by emulsion formation, desolvation, and coacervation 
methods [12-15]. In addition, albumin was employed 
to  produce  photosensitizer-conjugated  drug  carriers 
for cancer treatment [16]. To increase the driving force 
for  nanoparticle  formation,  specific  hydrophobic 
molecules  have  been  conjugated  to  native  albumin, 
given  that  hydrophobic  drugs  can  be  successfully 
loaded into albumin-based nanoparticles [15]. How-
ever, there are still a number of problems associated 
with  the  development  of  albumin  nanoparticles  as 
drug  carriers,  including  complicated  fabrication 
methods,  wide  size  distribution,  instability  under 
physiological  conditions,  and  the  unintended  burst 
release of drugs [17]. 
 Herein, chlorin e6 (Ce6)-conjugated HSA nano-
particles (Ce6-HSA-NPs) are introduced as photody-
namic drug delivery candidates with biocompatibility 
and  tumor-targeting  abilities.  To  produce  tu-
mor-targeting albumin nanoparticles, the hydropho-
bic  photosensitizer  Ce6  was  directly  conjugated  to 
albumin. Chlorin e6 was chosen as an attractive hy-
drophobic  core,  providing  the  driving  force  for 
self-assembly.  In  this  paper,  the  synthesis  of 
Ce6-HSA-NPs is reported, as well as the measurement 
of the photo-physical properties of the nanoparticles, 
such as size distribution and the production of singlet 
oxygen. The cellular uptake and laser-triggered pho-
totoxicity of these nanoparticles were also evaluated 
in a cell culture system. Finally, the time-dependent 
biodistribution  and  the  therapeutic  efficacy  of  the 
nanoparticles in vivo were investigated in HT-29 hu-
man  colon  cancer-bearing  mice.  The  results  of  this 
study  indicate  that  the  Ce6-HSA-NPs  may  exhibit 
prolonged  circulation  in  the  blood  along  with  en-
hanced  tumor  specificity  and  improved  therapeutic 
efficacy. 
Materials and Methods  
Materials.  
Human  serum  albumin  (HSA,  Average 
MW=67,000), Ce6, N-hydroxysuccinimide (NHS), and 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide  hy-
drochloride  (EDC)  were  purchased  from  Sigma  (St. 
Louis, MO). Anhydrous dimethyl sulfoxide (DMSO) 
and methanol were obtained from Merck (Darmstadt, 
Germany). All other chemicals and solvents were of 
analytical grade and were used without further puri-
fication. HeLa human cervical cancer cells and HT-29 
human  colon  cancer  cells  were  obtained  from  the 
American Type Culture Collection (Rockville, MD). 
Preparation of Ce6-HSA-NPs. 
To  prepare  Ce6-HSA-NPs,  Ce6  and  HSA  were 
conjugated together in a DMSO/water co-solvent, as 
described below. (The ratio of DMSO to distilled wa-
ter in the co-solvent was 1:9.) HSA powder (50 mg) 
was  dissolved  in  phosphate  buffered  saline  (PBS) 
(pH=7.4, 9 ml). Three different quantities of Ce6 (2.3, 
4.5, and14.25 mg, corresponding to a mole ratio of Ce6 
to HSA of 5, 10, and 30:1, respectively) were dissolved 
in DMSO (1 ml), followed by the addition of 4.5 molar 
equivalent of NHS and EDC about Ce6. After allow-
ing the HSA and Ce6 solutions to completely dissolve, 
they were mixed slowly, and the reaction mixture was 
gently  stirred  for  1  day.  The  reaction  mixture  was 
dialyzed  for  3  days  against  methanol  and  distilled 
water to remove unconjugated Ce6 and DMSO and 
then lyophilized to produce a light green solid pow-
der containing the Ce6-HSA-NPs. The Ce6-HSA-NPs, 
which, as noted above, were synthesized with 5, 10, or 
30 Ce6 molecules per one molecule of HSA (denoted 
as  Ce6-HSA-NP-5X,  Ce6-HSA-NP-10X  and 
Ce6-HSA-NP-30X,  respectively),  were  dissolved  in 
the DMSO/water co-solvent. The solutions were cen-
trifuged  three  times  for  10  min  at  13,200  rpm.  Fol-
lowing  each  centrifugation,  the  supernatants  were Theranostics 2011, 1 
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collected, the pellets were discarded, and the super-
natants were again lyophilized. 
Characterization of Ce6-HSA-NPs.  
The  diameter  and  size  distributions  of  the 
Ce6-HSA-NPs  were  measured  with  dynamic  light 
scattering (DLS) using a 127-35 laser (Spectra Physics, 
Mountain View, CA). Ce6-HSA-NPs were dispersed 
in PBS (1 mg/ml, pH 7.4, 37oC), and the size distribu-
tion was measured with a BI-9000AT digital autocor-
relator (Brookhaven, NY,  USA) operated at 633 nm 
and 37oC. The morphology of the nanoparticles was 
observed  using  a  transmission  electron  microscope 
(TEM) (CM30 electron microscope,  Philips, CA) op-
erated at an acceleration voltage of 80 kV. Samples (1 
mg/ml in distilled water) were placed on a 300-mesh 
copper  grid  coated  with  carbon.  After  drying,  each 
sample  was negatively stained using a droplet of 2 
wt%  uranyl  acetate  solution.  The  Ce6  conjugation 
efficiency of the Ce6-HSA-NPs was determined using 
a  Lambda  UV-Vis  7  spectrophotometer  (Per-
kin-Elmer,  CT).  A  DMSO/water  co-solvent  was 
added to the lyophilized nanoparticles (1 mg/ml) to 
obtain a clear solution. (The ratio of DMSO to distilled 
water was 1:9, as noted above.) The concentration of 
the conjugated Ce6 was quantified by measuring the 
absorbance at 405 nm and comparing the reading to a 
standard concentration curve of free Ce6 in the same 
DMSO/water co-solvent. 
Singlet oxygen generation from Ce6-HSA-NPs.  
The  capacity  of  singlet  oxygen  generation  was 
observed  using  p-nitroso-N,  N′-dimethylaniline 
(RNO)  as  a  singlet  oxygen  sensor.  The  method  of 
bleaching  the  corresponding  endoperoxide  of  RNO 
was used to measure the quantum yields of singlet 
oxygen [18]. Briefly, 100 μl of RNO in heavy water 
(D2O, 250 μM) and 300 μl of histidine in D2O (0.03 M) 
were dissolved separately and then mixed together in 
a  quartz  cuvette.  Free  Ce6  (1  μg,  6.67  μM)  and 
Ce6-HSA-NPs (1 μg of Ce6) were dissolved in 700 μl 
of a D2O solution containing 1% DMSO. To measure 
the singlet oxygen generation, 700 μl of each solution 
was added to the RNO solution. Before measuring the 
singlet oxygen generation, the solution was bubbled 
with water-saturated oxygen for 10 min, and the so-
lution  was  then  irradiated  with  a  laser  (671  nm  6 
Jcm-2) for 30 min. The optical density at 440 nm (max 
of RNO) was  monitored every 2 min  using a spec-
trophotometer (ISS, Champaign, IL).  
Cellular uptake of Ce6-HSA-NPs.  
HeLa cells were cultured with Dulbecco’s Modi-
fied Eagle’s Medium (DMEM) (Gibco, Grand Island, 
NY) containing 10% fetal bovine serum (FBS) (Gibco). 
To  monitor  the  cellular  uptake  of  Ce6-HSA-NPs, 
HeLa cells (2×105 cells) were seeded onto 6-well plates 
and  allowed  to  attach  for  1  day.  The  next  day,  the 
medium was replaced with 2 ml of serum-free me-
dium, and cells were treated with free Ce6 (2.5 μg/ml) 
or Ce6-HSA-NPs (2.5 μg/ml of Ce6) for 1 h. The cells 
were then washed twice with PBS containing Ca2+ and 
Mg2+ and stained with DAPI (300 nM) for 5 min. After 
staining, cells were washed twice with PBS containing 
Ca2+ and Mg2+ and then fixed with 4% paraformal-
dehyde.  Using  a  fluorescence  microscope  (IX81, 
Olympus), the cellular uptake and subcellular locali-
zation  of  the  Ce6-HSA-NPs  were  monitored  under 
high  resolution.  The  fluorescence  images  were  ob-
served  with  a  DAPI  filter  set  (Ex=360–370  nm, 
Em=420–460 nm) and a Cy5.5 filter set (Ex=640–660 
nm, Em=712–730 nm). 
Laser-triggered phototoxicity of Ce6-HSA-NPs 
in a tumor cell culture system.  
To compare the phototoxicity between the free 
Ce6 and the Ce6-HSA-NPs, HT-29 cells (1×104 cells) 
were seeded onto 96-well cell culture plates and in-
cubated for 1 day. The medium in each well was then 
replaced with 200 μl of serum-free medium contain-
ing free Ce6 (0.5, 1, 2, 4, or 8 μg/ml) or Ce6-HSA-NPs 
(employing  the  same  concentrations  as  free  Ce6). 
Control cells received only serum-free medium. The 
cells were then incubated for 1 h, and then washed 
twice  with  PBS  before  fresh  culture  medium  was 
added.  Following  these  procedures,  the  cells  were 
irradiated  with  an  LED  lamp  (670–690  nm  wave-
length) for 20 min and incubated at 37oC for 24 h. Cell 
viability was measured by the MTT colorimetric assay 
and  recorded  as  the  percentage  of  live  cells  in  the 
treated samples compared with the percentage of live 
cells  in  the  untreated  control.  The  assay  was  per-
formed five times to ensure statistical significance. To 
visualize  dead  cells  in  vitro  after  PDT,  HT-29  cells 
(2×105 cells)  were  cultured  for  2  days  in  6-well  cell 
culture plates on cover-slips which had been coated 
with  gelatin.  The  cells  were  then  irradiated  with  a 
He-Ne laser (671 nm, 6 J/cm2) for 2 min and stained 
with trypan blue dye for 5 min. 
Tumor-targeting efficiency of Ce6-HSA-NPs in 
HT-29 tumor-bearing mice.  
To evaluate the in vivo biodistribution of free Ce6 
and Ce6-HSA-NPs, 5-week-old HT-29 tumor bearing 
athymic nude mice were prepared (Institute of Med-
ical Science, Tokyo). Subcutaneous tumors were es-
tablished by intravenous (i.v.) injection of HT-29 cells 
(5×106 cells) into the left side of the back of the mice. 
When  the  tumor  volume  reached  approximately Theranostics 2011, 1 
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150–200  mm3,  a  saline  solution  of  free  Ce6  or 
Ce6-HSA-NPs containing 2.5 mg/kg of Ce6 was in-
jected  through  the  tail  vein  into  the  tumor-bearing 
mice. After injection, the biodistribution of free Ce6 
and Ce6-HSA-NPs within the mice was monitored by 
using the eXplore Optix system (Advanced Research 
Technologies Inc., Montreal, Canada). The mice were 
placed on an animal plate that was heated to 36oC. 
Laser power and count time sets were optimized at 6 
μW and 0.3 s per point. The excitation and emission 
spots were raster-scanned in 1-mm steps over the re-
gion  of  interest  to  generate  emission  wavelength 
scans. A 670-nm pulsed laser diode was used to excite 
the Ce6 molecules. Long wave fluorescence emission 
(600–700 nm) was detected using a fast photomulti-
plier tube (Hamamatsu, Japan) and a time-correlated 
single  photon  counting  system  (Becker  and  Hickl 
GmbH, Berlin, Germany). 
For  determine  the  blood  clearance  of  free  Ce6 
and Ce6-HSA-NPs, venous blood samples were col-
lected  with  heparin  coated  syringe  (31G  needle)  at 
each time point (1, 6, 12 and 24 h). Plasma were pre-
pared and measured Ce6 fluorescence intensity with a 
Cy5.5 filter set using a 12-bit CCD camera (Image Sta-
tion  4000  MM;  Kodak,  New  Haven,  CT)  equipped 
with a special C-mount lens and a long wave emission 
filter (600 to 700 nm; Omega Optical). 
To compare the tissue and tumor accumulation 
of free Ce6 and Ce6-HSA-NPs, mice were sacrificed 
after 2 days following i.v. injection of either free Ce6 
or  Ce6-HSA-NPs  (2.5  mg/kg  of  Ce6),  respectively. 
The excised tissues included the livers, lungs, spleens, 
kidneys,  and  hearts,  as  well  as  the  tumors.  Tissues 
were  analyzed  by  measuring  the  Ce6  fluorescence 
intensity  with a Cy5.5 filter set  using a 12-bit CCD 
camera (Image Station 4000 MM; Kodak, New Haven, 
CT) equipped with a special C-mount lens and a long 
wave emission filter (600 to 700 nm; Omega Optical). 
A quantification of the in vivo tumor target specificity 
of free Ce6 and Ce6-HSA-NPs was recorded as total 
photons  per  centimeter  squared  per  steradian 
(p/s/cm2/sr) per tumor (n=3 mice per group). 
Therapeutic efficacy of Ce6-HSA-NPs in HT-29 
tumor-bearing mice.  
As described above, HT-29 tumors were estab-
lished  in  athymic  nude  mice.  When  the  tumor  size 
reached approximately 125  25 mm3, saline, free Ce6 
(2.5 mg/kg of Ce6), and Ce6-HSA-NPs (2.5 mg/kg of 
Ce6) were injected into the mice via the tail vein. At 4 
h and 12 h post-injection, mice (each group, n=3) were 
irradiated (two times, 30 min each time) at the tumor 
site with a laser (671 nm, 6 J/cm2). The therapeutic 
efficacy  of  the  treatments  was  next  monitored  by 
measuring  the  tumor  volumes  calculated  as  1/2  × 
(length × width2) with a caliper for 25 days. In addi-
tion, at 10 days after laser irradiation, tumor tissues 
were isolated from the mice, fixed with 4% paraform-
aldehyde, and embedded in paraffin. The sliced tu-
mor  tissues  (6  μm)  were  stained  with  hematoxylin 
and eosin (H&E) to evaluate the induction of necrosis 
or apoptosis. 
Results & Discussion 
In  the  present  study,  tumor-targeting  albu-
min-based nanoparticles were prepared as an efficient 
carrier  of  the  photosensitizer,  Ce6.  The  valuable 
properties of the Ce6-carrying nanoparticles, such as 
self-assembly, particle stability, singlet oxygen gener-
ation, cellular uptake, and in vitro phototoxicity, were 
precisely evaluated. Based on these data, the particles 
were ultimately subjected to in vivo PDI and PDT in a 
tumor-bearing mouse model. 
First, Ce6 was conjugated to the amine groups of 
the  lysine  residues  within  HSA  so  as  to  form 
self-assembling nanoparticles for PDT (Figure 1A). To 
optimize the content of Ce6 within the Ce6-HSA-NPs 
for  evaluation  of  in  vivo  stability  and  high  tu-
mor-targeting  ability,  variable  amounts  of  Ce6  (5:1, 
10:1, 30:1 mole ratio per HSA) were used in the con-
jugation reaction. Carboxylic groups of Ce6 were ac-
tivated by EDC/NHS, and amide bonds were formed 
with the amine residues of HSA through an overnight 
reaction. To determine the optimized Ce6 conjugation 
ratio, the amounts of grafted Ce6 were measured by 
the  UV  spectra  method.  As  shown  in  Table  1, 
Ce6-HSA-5X,  Ce6-HSA-10X,  and  Ce6-HSA-30X 
demonstrated  59.1%,  76.4%  and  38.6%  grafting  effi-
ciency, respectively. Residual Ce6s were significantly 
removed  by  long-term  dialysis  with  DMSO/water 
co-solvent.  The  grafting  amount  of  Ce6  did  not  in-
crease more than approximately 14 molecules to one 
albumin molecule. The fact that the grafting efficiency 
of Ce6-HSA-30X was decreased was likely due to the 
fact that the reactivity of some of the amines within 
HSA was limited due to stearic hindrance in the al-
bumin  molecule  [19].  Therefore,  Ce6-HSA-10X  was 
used for all further studies. 
Table 1. Feed ratio and grafting efficiency of 
Ce6-HSA-NPs. 
Sample  Grafting amount  Grafting efficiency (%) 
Ce6-HSA-NP-5Xa   8.76  59.1 
Ce6-HSA-NP-10X  14.36  76.4 
Ce6-HSA-NP-30X  14.44  38.6 
aThis number denotes the molar feed ratio of Ce6 to one HSA mol-
ecule. 
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Under aqueous conditions, the resulting conju-
gates formed stable self-assembled  nanoparticles by 
hydrophobic interactions between Ce6 molecules. The 
diameter and size distribution of these Ce6-HSA-NPs 
dispersed in PBS (pH 7.4, 37C) was measured using 
DLS. The nanoparticles were about 80–100 nm in di-
ameter with a stable size distribution and a lack of 
aggregation, and showed good solubility in contrast 
to hydrophobic free Ce6 molecules (Figure 1B). The 
average diameter and size distribution  of the nano-
particles was maintained for 7 days (data not shown). 
TEM  images  also  confirmed  their  spherical  shape, 
nano-size, and narrow size distribution (Figure 1C). 
We  think  the  different  size  of  Ce6-HSA-NPs  in  be-
tween DLS data and TEM image was originated from 
the increase of hydrodynamic volume of nanoparti-
cles in aqueous condition. TEM image was obtained 
with dried samples, but DLS data was determined in 
aqueous  condition.  This  nano-size  distribution  is 
about 10-fold larger than the native albumin molecule 
and is expected to demonstrate increased tumor ac-
cumulation, resulting from both longer periods in the 
blood and the EPR effect, as discussed above and in 
previous studies [11, 20, 21]. Furthermore, the nature 
of  this  drug  conjugation  could  minimize  the  unin-
tended  burst  release  and  the  consequential  loss  of 
photosensitizers during blood circulation. 
 
 
Figure 1. Synthesis and characterization of Ce6 conjugated-human serum albumin nanoparticles (Ce6-HSA-NPs). (A) 
Illustration of self-assembled Ce6-HSA-NPs, (B) Size distribution of Ce6-HSA-NPs (inset images are vials containing PBS 
solutions of free Ce6 and Ce6-HSA-NPs). (C) TEM image of Ce6-HSA-NPs (D) Singlet oxygen generation of free Ce6 and 
Ce6-HSA-NPs according to irradiation time. 
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The singlet oxygen generation of Ce6-HSA-NPs 
was measured using RNO as a singlet oxygen sensor 
and a UV spectrometer (Figure 1D). HSA dissolved in 
1% DMSO did not cause any reactive oxygen produc-
tion after illumination by laser treatment. However, 
following  illumination  of  Ce6,  optical  density  de-
creased rapidly, indicating the generation  of singlet 
oxygen. In the case of Ce6-HSA-NPs, the singlet oxy-
gen generation in the 1% DMSO solution was similar 
to  that  produced  by  illuminated  free  Ce6,  demon-
strating that the therapeutic activities of the Ce6 mol-
ecules in Ce6-HSA-NPs were not changed after con-
jugation to HSA molecules. 
Next,  cellular  uptake  of  free  Ce6  and 
Ce6-HSA-NPs by HeLa cells was imaged using con-
focal fluorescence microscopy (Figure 2A). The chlo-
rin ring structure of Ce6 generates a strong fluores-
cence signal, enabling confirmation of the uptake and 
intracellular localization of the molecule through deep 
red  fluorescence  emission  (Ex=640–660  nm, 
Em=712–730  nm).  In  comparison  with  free  Ce6, 
Ce6-HSA-NPs  showed  similar  cellular  uptake,  and 
the amount of Ce6 in the cytosol was not decreased 
following  conjugation  to  HSA.  To  evaluate  cellular 
localization of Ce6-HSA-NPs, the nucleus was stained 
with DAPI, and the localization of Ce6 was observed 
in  high  resolution  images  after  uptake  of 
Ce6-HSA-NPs. As shown in Figure 2B, the red fluo-
rescence of the Ce6-HSA-NPs was not observed in the 
nucleus (stained blue using DAPI) and was only lo-
calized in the cytoplasm. Because the main target of 
photosensitizers is mitochondrial, this result suggests 
the possibility of effective tumor cell death resulting 
from PDT with Ce6-HSA-NPs. 
 
Figure 2. Cellular uptake and in vitro phototoxicity of Ce6-HSA-NPs. (A) Cellular uptake of free Ce6 and Ce6-HSA-NPs 
into HeLa cells. (B) Intracellular localization of Ce6-HSA-NPs with blue DAPI staining. (C) MTT assay in HeLa cells treated 
with free Ce6/Ce6-HSA-NPs and 20 min of LED lamp irradiation. (D) Trypan blue staining images of HeLa cells irradiated 
with laser for 30 min after treating Ce6-HSA-NPs. 
Laser treated
No treated
0 2 4 6 8
0
20
40
60
80
100
 
 
C
e
l
l
 
V
i
a
b
i
l
i
t
y
 
(
%
)
Concetration of Ce6 (ug/ml)
 Ce6
 Ce6-HSA-NPs
B A
C D
10um
1um
Ce6
Ce6-HSA-NPsTheranostics 2011, 1 
 
http://www.thno.org 
236 
To  evaluate  the  phototoxicity  in  vitro  of 
Ce6-HSA-NPs, HT-29 cells were incubated with free 
Ce6 and Ce6-HSA-NPs for 1 h and then washed with 
PBS. Next, cells were irradiated using a laser for 20 
min, and cell viability was determined using the MTT 
assay  (Figure  2C).  No  cytotoxicity  was  observed  in 
the case of HSA regardless of irradiation, and almost 
all of the cells were viable in the case of both free Ce6 
and Ce6-HSA-NPs in the absence of irradiation (data 
not shown). However, following irradiation with the 
appropriate  wavelength  of  light,  cell  viability  dra-
matically decreased according to the concentration of 
Ce6  in  HT-29  cells  treated  with  free  Ce6  and 
Ce6-HSA-NPs.  Laser-triggered  phototoxicity  of 
Ce6-HSA-NPs  was  also  observed  using  the  trypan 
blue viability assay (Figure 2D). After 1 min of irra-
diation,  blue  spots  were  observed  only  in  the  la-
ser-treated regions, which demonstrated that most of 
irradiated cells were severely damaged or destroyed. 
In  the  same  slide,  cells  outside  the  laser-irradiated 
area were mostly viable (data not shown). This result 
demonstrated similar in vitro phototoxicity of free Ce6 
and Ce6-HSA-NPs and was in accordance with singlet 
oxygen generation and cellular uptake data. 
Based  on  the  intrinsic  fluorescence  of  Ce6,  the 
tumor-targeting  ability  of  Ce6-HSA-NPs  in  HT-29 
tumor-bearing mice was evaluated in a noninvasive 
manner. After i.v. injection of free Ce6 (2.5 mg/kg) 
and  Ce6-HSA-NPs  (2.5  mg/kg  of  Ce6)  into  the  tail 
vein, the time-dependent biodistribution of free Ce6 
and  Ce6-HSA-NPs  was  monitored  using  an  in vivo 
optical imaging system (Figure 3A). When free Ce6 
was injected into the mice, a strong fluorescent signal 
was observed primarily in liver tissues, and the signal 
in the whole body was only maintained for up to 6 h. 
This result indicated that injected free Ce6 was elim-
inated rapidly, providing low accumulation in tumor 
tissues.  However,  in  case  of  Ce6-HSA-NP-treated 
mice, an enhanced fluorescent signal throughout the 
whole body persisted for nearly 12 h, and the signal at 
the  tumor  site  was  stronger  than  that  observed  in 
other tissues. Hence, the prolonged circulation time of 
Ce6-HSA-NPs in the blood was mainly attributed to 
the high accumulation of the nanoparticles in the tu-
mor  tissue.  The  time-dependent  accumulation  of 
Ce6-HSA-NPs  in  tumor  tissue  is  clearly  shown  in 
Figure 3B, and the fluorescent signal was far stronger 
than that observed in the free Ce6-treated mice. Im-
portantly,  even  after  1  h  post-injection  of 
Ce6-HSA-NPs,  subcutaneous  tumors  were  detected 
against the surrounding background tissue, indicating 
the  possible  use  of  nanoparticles  for  PDI,  as  men-
tioned  above.  The  fluorescent  signal  exhibited  its 
maximum intensity at 12 h post-injection and gradu-
ally decreased for 2 days. In addition, the total photon 
counts from Ce6-HSA-NPs in the tumor tissue were 
about 13.7-fold higher compared with that of free Ce6 
(Figure 3C). To investigate the blood circulation dy-
namics  of  Ce6-HSA-NPs,  we  monitored  and  com-
pared  free  Ce6  or  Ce6-HSA-NPs  blood  circulation 
(Figure  3D).  Ce6-HSA-NPs  showed  prolonged  and 
slow clearance kinetics within blood until 24 h, while 
free  Ce6  particles  rapidly  decreased  its’  fluorescent 
intensity, this was accordance with tumor accumula-
tion result. One hour later, free Ce6 was hard to detect 
from the vein, but Ce6-HSA-NPs could circulate more 
than 12 h. It represented significant prolonged blood 
circulation  effect  of  conjugated  nanoparticle  form. 
Upon  ex  vivo  evaluation  of  excised  tissues  at  48  h 
post-injection,  Ce6-HSA-NP-treated  mice  showed  a 
strong fluorescent intensity in the tumor tissue, but 
unfortunately,  the  fluorescent  intensity  in  the  liver 
tissue was even stronger (Figure 3E). This indicated 
that  although  a  large  number  of  Ce6-HSA-NPs  ac-
cumulated  in  tumor  tissues,  the  nanoparticles  also 
accumulated in the liver. This result may be explained 
by the fact that Kupffer cells in the liver play a role to 
uptake  and  degrade  proteins,  including  albumin. 
However, this may not be a critical problem in case of 
PDT, because the light source cannot penetrate inside 
liver tissue. 
To  evaluate  the  therapeutic  efficacy  of 
Ce6-HSA-NPs  in  HT-29  tumor-bearing  mice,  HT-29 
tumors were established in athymic nude mice as de-
scribed above. Then, saline, free Ce6 (2.5 mg/kg of 
Ce6),  and  Ce6-HSA-NPs  (2.5  mg/kg  of  Ce6)  were 
injected into the mice via the tail vein. Mice were ir-
radiated  at  the  tumor  site  (two  times;  30  min  each 
time) with a He-Ne laser at 4 h and 12 h post-injection. 
The appropriate time for laser irradiation was opti-
mized  through  several  pre-test.  At  2  days 
post-injection,  Ce6-HSA-NP-treated  mice  demon-
strated a severe tumor necrosis at the site of the laser 
irradiation. These significant therapeutic effects were 
not  observed  in  the  free  Ce6-treated  group  (Figure 
4A). Seven days later, it was apparent that the necrotic 
scar  tissue  was  healing  and  that  normal  tissue  had 
begun to regenerate in the Ce6-HSA-NP-treated mice. 
The therapeutic efficacy of each treatment was moni-
tored by evaluating the tumor volumes for 25 days 
(Figure 4B).  
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Figure 3. In vivo photodynamic imaging with Ce6-HSA-NPs in tumor-bearing mouse model. (A) in vivo time-dependant 
whole body imaging of athymic nude mice bearing HT-29 tumors after i.v. injection of free Ce6 and Ce6-HSA-NPs (5mg/kg 
of Ce6). (B) In vivo tumor target specificity imaging of (A). (C) Quantification of fluorescence signals in tumor site of (A) (total 
photon counts per centimeter squared per steradian (p/s/cm²/sr) per each tumor). (D) Blood fluorescence of free Ce6 and 
Ce6-HSA-NP injected HT-29 tumor-bearing mice and the quantification of fluorescent intensity (n=3). (E) Ex vivo images of 
normal  organs  (liver,  lung,  spleen,  kidney  and  heart)  and  tumors  excised  at  2  days  post-injection  of  free  Ce6  and 
Ce6-HSA-NPs. 
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Figure 4. In vivo photodynamic therapy with Ce6-HSA-NPs in tumor-bearing mouse model. (A) Resulting images of In vivo 
photodynamic therapy after i.v. injection of free Ce6 and Ce6-HSA-NPs (2.5mg/kg of Ce6) and 30 min irradiation at tumor 
site with a laser (671nm, 6 Jcm
-2) after 4hr and 12hr post-injection. (B) Tumor growth data of (A) measured for 25 days. Data 
represent mean ± s.e. (The paired Student's test was used for statistical analysis and * denotes significant diffrerence defined 
as P < 0.05.) (C) H&E staining of tumor tissue of (A) at 10 days after treatment. Original magnification is x100. 
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Free Ce6-treated mice showed a reduced tumor 
volume  of  about  34%  compared  with  saline-treated 
mice. Ce6-HSA-NP-treated mice demonstrated a sig-
nificantly greater tumor reduction of 70% due to the 
high tumor-targeting efficacy of the nanoparticles. At 
10 days after laser irradiation, the therapeutic result 
was further evaluated by histological tissue staining 
with H&E to confirm the tissue damage (Figure 4C). 
Saline-injected  mice  showed  tumor  cells  with  rare 
apoptosis or necrosis. However, in mice treated with 
Ce6-HSA-NPs, most of the tumor tissue was severely 
destroyed by irradiation, making it difficult to locate 
the tumor lesion. Instead, fibrotic tissue was observed 
behind the epidermis. By contrast, incomplete tumor 
destruction  was  observed  in  mice  treated  with  free 
Ce6 and irradiation.  
In summary, we have developed novel biocom-
patible  tumor-targeting  nanoparticles  for  efficient 
PDT  of  cancers.  The  nanoparticles  were  formed  by 
self-assembly  of  photosensitizer-conjugated  HSAs. 
The  therapeutic  activity  of  Ce6  molecules  in  these 
Ce6-HSA-NPs  was  not  decreased  after  conjugation, 
and the Ce6 generated cytotoxic singlet oxygen upon 
irradiation.  Ce6-HSA-NPs  exerted  higher  tumor 
specificity  and  therapeutic  efficacy  compared  with 
free  Ce6  following  irradiation  and  singlet  oxygen 
generation.  The  high  accumulation  in  tumor  tissue 
and efficient therapy with Ce6-HSA-NPs was mainly 
caused by prolonged circulation in the blood in addi-
tion  to  the  EPR  effect  for  the  production  of  stable 
nano-structures  [20,  21].  These  results  demonstrate 
the promising potential of Ce6-HSA-NPs as effective 
tumor-targeting carriers for PDT of various cancers. 
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